Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule products for the treatment of orphan neuromuscular diseases, an area of high unmet medical needs.

Products & Pipeline

Santhera has three compounds in development for seven orphan neuromuscular indications. Catena® is Santhera's first product, approved under conditions in Canada for symptomatic treatment of Friedreich's Ataxia.

Clinical Development Programs

Santhera is currently recruiting patients for clinical studies in Duchenne Muscular Dystrophy, MELAS and Primary Progressive Multiple Sclerosis.

Latest News

July 15, 2010
Data from Santhera's Catena® in Leber's Hereditary Optic Neuropathy Will Be Presented at the mitoNET Congress for Mitochondrial Medicine 2010
---
June 16, 2010
Santhera's Catena® Improved Vision in Patients with Leber's Hereditary Optic Neuropathy; Regulatory Submissions Planned in First Half of 2011